Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development
The mortgage is structured with a two-year term, carrying interest rates of 12% for the first year and 13% for the second, with payments split 50% in cash and 50% in common stock.Agenus Inc. (NASDAQ:AGEN) shares are trading higher in the morning session on Wednesday.
艾吉納斯公司（納斯達克：AGEN）的股票在週三的早盤交易中上漲。
The company has secured a $22 million non-amortizing mortgage, backed by its Berkeley-based Biologics CMC facility and its 66-acre biomanufacturing-zoned property in Vacaville, California.
該公司獲得了一筆2200萬的非攤銷抵押貸款，抵押其位於伯克利的生物製品CMC設施和位於加利福尼亞州瓦卡維爾的66英畝生物製造區物業。
The deal, facilitated by L&L Capital, provides $20 million in net proceeds after closing costs and interest reserve, boosting Agenus' cash position ahead of anticipated further cash infusions in the coming months.
這筆交易由L&L資本促成，在扣除交易成本和利息儲備後提供2000萬的淨收益，增強了艾吉納斯在未來幾個月中預期進一步現金注入之前的現金狀況。
The mortgage is structured with a two-year term, carrying interest rates of 12% for the first year and 13% for the second, with payments split 50% in cash and 50% in common stock.
這筆抵押貸款的結構爲兩年期，第一年的利率爲12%，第二年爲13%，還款分爲50%現金和50%普通股票。
In parallel, Agenus is executing a Strategic Operational Realignment Plan to focus its efforts on its promising botensilimab/balstilimab (BOT/BAL) in MSS colorectal cancer (CRC).
同時，艾吉納斯正在執行一項戰略運營重組計劃，以將其工作重點放在對MSS結腸直腸癌（CRC）有前景的botensilimab/balstilimab（BOT/BAL）上。
Also Read: Major US Stock Futures Slide, Small-Caps Buck Trend: Market Strategist Flags This As The 'Stronger Times Of The Year For Stocks'
另請閱讀：主要美國股票期貨下滑，小型股逆勢而上：市場策略師指出這是『股票的強勁時期』
The plan includes a projected 60% reduction in annual external expenditures and a transition of the company's CMC capabilities into a fee-for-service biologics manufacturing business. These measures, along with additional planned optimizations, are expected to reduce Agenus' FY 2025 cash burn to approximately $100 million.
該計劃包括每年外部支出預計減少60%以及將公司的CMC能力轉型爲按服務收費的生物製品製造業務。這些措施，加上其他計劃的優化，預計將使艾吉納斯在2025財年的現金消耗減少到約10000萬。
BOT/BAL has demonstrated strong clinical activity in MSS CRC and other cancers resistant to existing therapies. Agenus is preparing for late-stage development and regulatory strategies, targeting both regional and global registration pathways. The company's strategic realignment aims to revolutionize cancer treatment while positioning Agenus for long-term growth and patient impact.
BOT/BAL在MSS CRC和其他對現有療法耐藥的癌症中表現出強大的臨床活性。艾吉納斯正在爲晚期開發和監管策略做準備，目標是區域型和全球註冊途徑。公司的戰略重組旨在徹底改變癌症治療，同時爲艾吉納斯的長期增長和患者影響做好定位。
Price Action: AGEN shares are trading higher by 16.3% to $3.93 at last check Wednesday.
價格走勢：截至週三最後一次檢查，艾吉納斯的股票上漲16.3%，至3.93美元。
Read next:
繼續閱讀：
- JD Vance's Investment Playbook Has Bitcoin And ETFs: Here's What Else The VP-Elect Is Betting On
- JD Vance的投資策略包括比特幣和etf：副總統候選人還押注於其他什麼。
Image via Unsplash.
通過Unsplash獲取圖片。
譯文內容由第三人軟體翻譯。
